Key takeaways
- Cencora's earnings per share of $4.66 surpassed the $4.58 estimate.
- Revenue reached $88.35 billion, exceeding the $87.95 billion estimate.
- The company reported strong revenue growth and provided key valuation metrics, including a trailing price-to-earnings ratio of 18.9.
Cencora (NYSE: COR) reported earnings before the market opened on November 4, 2026. Cencora distributes medicines and provides services to pharmacies, hospitals, and drug makers. Its earnings per share were $4.66, above the $4.58 estimate, while revenue was $88.35 billion, above the $87.95 billion estimate.
Revenue shows how much a company brings in before expenses. Cencora’s reported fiscal fourth-quarter revenue was $88.4 billion, up 5.5% from a year earlier, as highlighted by Business Wire. The $88.4 billion reported figure is rounded, while the $88.35 billion figure provides more detail. Full-year revenue rose 5.0% to $337.4 billion.
Cencora also reported GAAP diluted earnings per share of $2.71 for the quarter, compared with a loss of $1.75 per share a year earlier. GAAP earnings follow standard accounting rules. The company’s trailing price-to-earnings ratio is 18.9, meaning its share price is 18.9 times its earnings over the past 12 months.
Other measures give a broader view of Cencora’s valuation and finances. Its price-to-sales ratio is 0.19, and its enterprise-value-to-sales ratio is 0.21; enterprise value includes debt as well as the value of its shares. Its debt-to-equity ratio is 3.06, while its current ratio of 0.94 compares short-term assets with short-term liabilities.
